Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
UPDATE: Incyte (INCY) PT Raised to $83 at Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Overweight Rating on Johnson & Johnson (JNJ) Following 4Q
-
uniQure BV (QURE) PT Raised to $96 at Cantor Fitzgerald
-
Evolent Health (EVH) PT Raised to $16 at Cantor Fitzgerald
-
Makor Capital Hires Ian Epstein as New President of Its U.S. Global Macro Division
-
PlacementTracker Publishes 2019 PIPE and Private Placement Markets League Tables
-
IBM (IBM) PT Raised to $138 at Cantor Fitzgerald
-
Auryn Resources Inc (AUG:CN) (AUG) PT Lowered to Cdn$2.90 at Cantor Fitzgerald
-
Perrigo Co. (PRGO) PT Raised to $70 at Cantor Fitzgerald on Multiple Expansion
-
Freddie Mac Announces Pricing of $412 Million Multifamily Small Balance Loan Securitization
-
Orchid Island Capital Announces Estimated Fourth Quarter 2019 Results, January 2020 Monthly Dividend and December 31, 2019 RMBS Portfolio Characteristics
-
Pre-Open Stock Movers 01/16: (MNI) (SIG) (XPO) Higher (BK) (TSLA) (PPG) Lower (more...)
-
UPDATE: Cantor Fitzgerald Starts Compugen (CGEN) at Overweight
-
PolarityTE (PTE) Case Studies Reinforce Long Term Opportunity - Cantor Fitzgerald
-
Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option
-
Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option
-
Cantor Fitzgerald Reiterates Overweight Rating on PolarityTE (PTE) Following Meetings
-
HealthEquity, Inc (HQY) PT Lowered to $90 at Cantor Fitzgerald
-
Mudrick Capital Acquisition Corporation To Combine With Hycroft Mining Corporation
-
Mereo BioPharma Group (MERO) Reports Additional Positive Data from Phase 2b ASTEROID Study of Setrusumab in Adults with Osteogenesis Imperfecta; Provides Update on Regulatory Progress
-
Mereo BioPharma Announces Additional Positive Data from Phase 2b ASTEROID Study of Setrusumab in Adults with Osteogenesis Imperfecta and Provides Update on Regulatory Progress
-
Mereo BioPharma Announces Additional Positive Data from Phase 2b ASTEROID Study of Setrusumab in Adults with Osteogenesis Imperfecta and Provides Update on Regulatory Progress
-
Form 13F-HR CANTOR FITZGERALD INVEST For: Dec 31
-
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
-
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
-
Rumors Perrigo Co. (PRGO) Acquiring Akorn (AKRX) 'Likely Not True' - Cantor Fitzgerald
-
Two Pieces of Good News for Amarin (AMRN) - Cantor Fitzgerald
-
Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab
-
Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab
-
Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab
-
Dermira (DERM) Trades Above Deal Price on Speculation of Higher Bid
-
Aptinyx (APTX) Prices 10.17M Share Common Stock Offering at $3/shh
-
Aptinyx Announces Pricing of Public Offering of Common Stock
-
Aptinyx Announces Pricing of Public Offering of Common Stock
-
Intuitive Surgical (ISRG) PT Raised to 'Street High' $690 at Cantor Fitzgerald on Strong Q4
-
Cidara Therapeutics (CDTX) Announces Proposed $30M Rights Offering
-
Cidara Therapeutics Announces Proposed Rights Offering
-
Apellis Pharmaceuticals (APLS) Prices 9.5M Share Offering at $37/Sh
-
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Cantor Fitzgerald Starts Phreesia Inc. (PHR) at Overweight
-
Cantor Fitzgerald Starts BiomX (PHGE) at Overweight
-
Cantor Fitzgerald Defends Amarin (AMRN), Says Headlines 'Noise'
-
Amarin Corporation (AMRN) Updated Guidance In Line, Cantor Fitzgerald Reiterates Outperform
-
Intra-Cellular Therapies (ITCI) Prices 10M Share Common Offering at $29.50/Sh
-
Intra-Cellular Therapies Prices Public Offering of Common Stock
-
Hecla Mining (HL) PT Raised to $4 at Cantor Fitzgerald, After Reporting 22% Higher Silver and 4% Higher Gold Production
-
Apellis Pharmaceuticals (APLS) Data Exceeded Expectations, Expect Shares to Fly - Cantor Fitzgerald
-
Amarin Corporation (AMRN) Expenses May Drive Expenses Higher but Vascepa Peak Sales Remains the Key for Investors - Cantor Fitzgerald
-
Incyte (INCY) PT Lowered to $65 at Cantor Fitzgerald

